Association of GLP ‐1 Receptor Agonists Versus Other Antidiabetic Medications With Cardiovascular, Renal, and Liver Outcomes in Patients With Type 2 Diabetes
Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11194-11205
DOI: 10.1111/dom.71313 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 08.09.2026. Verfasst von Yuqing Fan und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases. Die Arbeit nennt 38 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To compare cardiovascular, kidney, and liver outcomes of Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) versus seven other antidiabetic medications (ADMs) in Chinese patients with Type 2 diabetes. Materials and Methods This retrospective cohort study (2018–2024) used an Eastern China regional healthcare database. We included patients initiating GLP‐1 RAs, sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2 inhibitors), dipeptidyl peptidase‐4 inhibitors (DPP‐4 inhibitors), insulins, sulfonylureas, α‐glucosidase inhibitors (AGIs), thiazolidinediones, or meglitinides. Outcomes were major adverse cardiovascular (MACE), kidney (MAKE), and liver (MALO) events. A propensity score‐based matching weights (MWs) approach was used to balance covariates including demographics, comorbidities, and medication use, and Cox proportional hazards models were conducted in both intention‐to‐treat and per‐protocol analyses.
Results
Among 105 391 patients, SGLT‐2 inhibitors (HR 1.19, 95% CI 1.10–1.30), insulins (HR 1.42, 95% CI 1.32–1.52), sulfonylureas (HR 1.30, 95% CI 1.18–1.43), and AGIs (HR 1.45, 95% CI 1.31–1.59) were associated with higher MACE risk compared with GLP‐1 RAs. DPP‐4 inhibitors (HR 3.09, 95% CI 1.69–5.63), insulins (HR 6.11, 95% CI 4.37–8.54), and meglitinides (HR 4.56, 95% CI 2.32–8.97) were associated with higher MAKE risk. Higher MALO risk was observed with DPP‐4 inhibitors (HR 1.48, 95% CI 1.21–1.79), insulins (HR 2.06, 95% CI 1.81–2.34), AGIs (HR 1.55, 95% CI 1.26–1.90), and meglitinides (HR 1.43, 95% CI 1.07–1.92).
Conclusions
GLP‐1 RAs were associated with favourable cardio‐renal‐metabolic outcomes compared with several second‐line glucose‐lowering agents, particularly insulins and sulfonylureas. These findings add to the real‐world evidence supporting the potential cardiovascular, renal, and hepatic benefits of GLP‐1 RAs in patients with T2DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China.
- School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
- Institute for Global Health and Development, Peking University, Beijing, China.
ORCID-Profile: Yuqing Fan, Nan Peng, Linfeng Jiang, Beini Lyu
Zitieren
APA
Fan, Y., Peng, N., Jiang, L., Wei, R., Lu, G., Zhang, S., Mu, C., Xue, M., Lyu, B., & Yao, D. (2026). Association of GLP ‐1 Receptor Agonists Versus Other Antidiabetic Medications With Cardiovascular, Renal, and Liver Outcomes in Patients With Type 2 Diabetes. Diabetes, Obesity and Metabolism, 28(12), 11194-11205. https://doi.org/10.1111/dom.71313
Vancouver
Fan Y, Peng N, Jiang L, Wei R, Lu G, Zhang S, et al. Association of GLP ‐1 Receptor Agonists Versus Other Antidiabetic Medications With Cardiovascular, Renal, and Liver Outcomes in Patients With Type 2 Diabetes. Diabetes, Obesity and Metabolism. 2026;28(12):11194-11205. doi:10.1111/dom.71313
BibTeX
@article{Fan2026,
author = {Fan, Yuqing and Peng, Nan and Jiang, Linfeng and Wei, Ruolan and Lu, Guoxian and Zhang, Shuo and Mu, Chen and Xue, Mengyao and Lyu, Beini and Yao, Dongning},
title = {Association of GLP ‐1 Receptor Agonists Versus Other Antidiabetic Medications With Cardiovascular, Renal, and Liver Outcomes in Patients With Type 2 Diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {12},
pages = {11194--11205},
doi = {10.1111/dom.71313}
}
EUVIMED